logo
welcome
Reuters

Reuters

Health

Health

Lilly needs a plan to spur weight-loss drug sales, investors say

Reuters
Summary
Nutrition label

80% Informative

Lilly last month forecast lower-than-expected fourth-quarter revenues for popular weight-loss drug Zepbound .

Investors and analysts want to hear details from the company on how exactly it plans to grow U.S. sales of the drug.

The company last month said in January that wholesalers had not restocked inventories as expected, driving shares down 8% .

VR Score

90

Informative language

96

Neutral language

71

Article tone

semi-formal

Language

English

Language complexity

57

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links